Damora Therapeutics (DMRA) vs First Tracks Biotherapeutics (TRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Damora Therapeutics is the larger company by market cap ($1.27 billion vs $1.14 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | TRAX |
|---|---|---|
| Share price | $20.56 | $32.01 |
| Market cap | $1.27B | $1.14B |
| 1-day change | +1.58% | +4.64% |
| YTD return | -10.65% | — |
| 1-year return | +93.05% | — |
| 5-year return | -75.95% | — |
| EPS (TTM) | $-0.25 | $-4.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $49.91 |
| 52-week low | $4.95 | $14.72 |
| Distance from 52-week high | -46.35% | -35.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +128.06% | +118.68% |
| Average volume | 531.94K | 738.52K |
| Shares outstanding | 61.74M | 35.73M |
| Employees | 7 | 104 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About First Tracks Biotherapeutics
TRAX stock →First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees
DMRA vs TRAX FAQ
Which is bigger, Damora Therapeutics or First Tracks Biotherapeutics?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.27B compared with $1.14B for First Tracks Biotherapeutics (TRAX).
Are Damora Therapeutics and First Tracks Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.